DotBio

Private

SingaporeHealthcare & Life Scienceshttps://dotbio.com/

Last Round

Early Funding

Aug 7, 2023

Total Funding Raised

$8.45M

Company Overview

DotBio is a biotechnology company that develops multi-functional and intracellular antibody therapies for immuno-oncology and other therapeutic areas using its proprietary DotBody modular platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

antibody discoveryimmuno-oncologybiotech platformmulti-specific antibodiesintracellular antibodiesdrug discoveryprotein engineeringantibody therapeuticsdrug developmentbiologicsin silico drug designAI drug discoveryantibody pipelinepharma partneringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DotBio Comps

Public and private peers based on sector, stage, and business model.

DotBio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

DotBio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Aug 7, 2023
Grant	Oct 23, 2020
Corporate Funding	Sep 15, 2020
Seed	Jul 30, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Ignacio Asial

Founder, CEO

Founding Team

Kelly Hew

Chief Operating Officer

Executive Team

DotBio Investors

Notable investors and investment history

DotBio investors
Investor	Rounds
Enterprise Singapore	Grant
NTUitive	Seed
National Foundation for Cancer Research	Early Funding
Gaorong Capital	Early Funding

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Aug 7, 2023
$5.6M raised led by Gaorong Capital and aim-hiaccelerator.

View all signals

DotBio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

DotBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DotBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore

Employee Range18

Year Founded2018

Last FundingAug 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.